When I was about 6 years old in the early ‘40s, my 16-year-old brother was sent to a sanitarium for tuberculosis patients. He ...

Celcuity Inc. soared on best-in-class Phase 3 breast cancer data. Click to see why I have a Buy rating on CELC due to data, ...

For more than 80 years, men have been told that testosterone fuels prostate cancer. But a more nuanced picture has emerged ...

Assessments used to calculate cardiovascular disease risk in the general population may not have the same predictive power ...

Cancer of the prostate has become the leading cause of cancer diagnoses among males in the United Kingdom. Its treatment, ...

Clinical data presented at ASCO 2025 showed an objective response rate (ORR) of 63% among all patients, with a median progression-free survival (PFS) of 7.7 months. Responses were seen across ...

The American Cancer Society projected for 2025 that there would be over 154,000 new cases of colorectal cancer and 52,900 deaths.

One of the main threads running through our most-read stories of 2025—as much as ever in the medtech industry writ large—is ...

The engagement establishes a multi-phase framework to support AI enabled capital efficient development of Teverelix, a next generation GnRH antagonist, as a first in class market product for acute ...

Currently on crutches, Hoy confirmed that he had broken his leg in the crash but is recovering at a pace that will allow him to be at the World Darts Championship final at the turn of the year.

Prostate cancer is the most common cancer in Canadian men (beside non-melanoma skin cancers), accounting for 22 percent of all cancers. Mirroring U.S. guidelines against PSA screening, uOttawa ...